Novavax
NVAX | NASDAQ
$8.06
-$0.46 (-5.45%)
At close: Nov 16, 2026, 4:00 PM ET
$8.07
+$0.01 (+0.14%)
After-hours:
Nov 16, 2026, 7:50 PM ET
Novavax Company Profile
Company profile explainedCompany Profile
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Key Executives
| Name | Position |
|---|---|
| John Charles Jacobs | President, Chief Executive Officer & Director |
| James Patrick Kelly | Executive Vice President, Chief Financial Officer & Treasurer |
| Mark Casey | Executive Vice President, Chief Legal Officer & Corporate Secretary |
| Richard Crowley | Executive Vice President & Chief Operating Officer |
| Elaine O'Hara | Executive Vice President & Chief Strategy Officer |
| Erika S. Trahan | Associate Director of Investor & Public Relations |
| Ian J. Watkins | Executive Vice President & Chief Human Resources Officer |
| Naina Zaman | Director of Investor Relations |
| Silvia Taylor | Executive Vice President, Chief Corporate Affairs Officer & Head of Novavax Sweden |
| Troy Morgan | Senior Vice President, Deputy General Counsel & Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 16, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 16, 2026 | SC 13D/A | [Amend] Filing |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 06, 2026 | S-8 | Filing |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Jun 23, 2026 | 4 | Filing |
| Jun 23, 2026 | 4 | Filing |
| Jun 23, 2026 | 4 | Filing |
Novavax
| Country | United States |
| IPO Date | Dec 5, 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 749 |
| CEO | John Charles Jacobs |
Contact Details
21 Firstfield Road Gaithersburg,
Maryland 20878 United States
Stock Details
| Ticker Symbol | NVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001000694 |
| CUSIP Number | 670002401 |
| ISIN Number | US6700024010 |
| SIC Code | 2836 |
Recent News
- 5 days ago / prnewswire.comNovavax to Participate in Jefferies London Healthcare Conference
- 6 days ago / zacks.comNovavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
- 11 days ago / zacks.comNVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline
- 11 days ago / marketbeat.comNovavax Q3 Earnings Call Highlights
- 12 days ago / seekingalpha.comNovavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
- 12 days ago / zacks.comNovavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
- 12 days ago / prnewswire.comNovavax Reports Third Quarter 2026 Financial Results and Operational Highlights
- 19 days ago / zacks.comNovavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- 19 days ago / prnewswire.comNovavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
- 19 days ago / prnewswire.comNovavax to Report Third Quarter 2026 Financial Results on November 5, 2026
Add to Watchlist
Select watchlists to add or remove NVAX